Dose escalation for AITL

"Indeed, the information available on clinicaltrials.gov indicates an active search for suitable participants. The study was first listed on April 30th, 2024 and last revised on the same date. A total of 112 individuals are sought from 8 distinct sites to partake in this trial."

"As per the information disclosed by the trial sponsor, Arvinas Inc., the primary aim of this study will involve assessing the percentage of participants experiencing Adverse Events within a 28-day period starting from their initial dosing with the investigational drug. This evaluation will consider aspects such as severity, seriousness, and any potential correlation to the study medication in order to gauge safety and tolerability levels. Furthermore, secondary endpoints will include analyzing Time to maximum concentration (Tmax) for ARV-393 - denoting when peak concentrations occur after administration; Minimum concentration (Cmin) for ARV-393 - representing lowest observed concentrations post-dosing"

"Presently, this research is actively enlisting participants at 8 different medical facilities. These sites are scattered across various regions such as Nashville, New Brunswick, and New york among other undisclosed locations. Opting for the nearest site could reduce travel commitments upon enrollment."

"Given that this is a Phase 1 trial with restricted evidence on safety and effectiveness, our team at Power rated the safety of Dose escalation as 1."

"Indeed, the details on clinicaltrials.gov specify that this clinical trial is actively seeking candidates. The trial was initially listed on 4/30/2024 and last revised on the same day. Recruitment aims to enroll 112 patients across 8 locations."